[A22-02] Dapagliflozin (kidney disease) - Addendum to Commission A21-109

Last updated 18.02.2022

Project no.:
A22-02

Commission:
Commission awarded on 11.01.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Kidneys and urinary system

Indication:

Adults with chronic kidney disease

Result of dossier assessment:

Unchanged after addendum:

  • Without symptomatic chronic heart failure as comorbidity: hint of considerable added benefit
  • With additional symptomatic chronic heart failure as comorbidity: hint of non-quantifiable added benefit
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-02-18 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form